The Salivary Cytokine Index is a novel, noninvasive method developed by NYU researchers that uses a composite score of salivary cytokines to measure the severity of periodontal inflammation. By analyzing specific pro- and anti-inflammatory markers in saliva, it offers a more convenient alternative to traditional clinical exams for monitoring gum disease and evaluating potential links to systemic health conditions.
The Salivary Cytokine Index is a research-based diagnostic method developed by the Kamer Lab at NYU College of Dentistry to noninvasively assess the severity of periodontal inflammation. By measuring specific cytokine levels in a patient's saliva, this tool provides an alternative to traditional, time-consuming clinical assessments like bleeding on probing or pocket depth measurements. It holds significant potential as a diagnostic marker for monitoring disease progression, evaluating treatment responses, and identifying systemic inflammation associated with other health conditions.
The technology utilizes weighted and unweighted indices to synthesize levels of six key salivary cytokines: the pro-inflammatory cytokines IL-1β, IL-6, IL-8, and TNF-α, as well as the anti-inflammatory cytokines IL-10 and IL-13. These indices, named the Cytokine Component Index (CCI) and the Composite Inflammatory Index (CII), show statistically significant correlations with the Periodontal Inflamed Surface Area (PISA) score. The collection process requires only a whole saliva sample, which can be gathered conveniently outside of a traditional dental office setting.
The technology is currently at TRL 3, reflecting proof-of-concept research. A pilot study involving 67 participants demonstrated a moderately strong correlation between the indices and clinical periodontal inflammation. Researchers state that further validation is required in larger, more diverse populations and across various health conditions and stages of periodontal disease before it can be used as a clinical diagnostic tool.
New York University is a comprehensive private research university anchored in New York City, enrolling a large, diverse student body and operating a global network of campuses. Corporate engagement is enabled by co‑located engineering and computing hubs in Brooklyn and Manhattan with shared labs and facilities for prototyping and field pilots. Integration with a major hospital system supports clinical translation, IRB processes, and access to real‑world data under stringent governance. Proximity to leading industries and a mature sponsored‑research function streamline scoping, NDAs, MSAs, and talent pipelines. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DOD, and a dedicated technology transfer office manages IP, licensing, and startup creation.